<DOC>
	<DOCNO>NCT00572572</DOCNO>
	<brief_summary>Aprepitant currently approve prophylaxis acute delay CINV highly emetogenic chemotherapy regimen , include cisplatin ; however , yet study multiple-day chemotherapy treatment program . This study compare addition aprepitant compare placebo administer day 3,4,5 chemotherapy administration acute CINV prophylaxis standard antiemetic prophylaxis day 6 7 delay CINV prophylaxis double-blind , randomize , crossover study design .</brief_summary>
	<brief_title>Aprepitant + 5HT3 + Dexamethasone Patients With Germ Cell Tumors</brief_title>
	<detailed_description>OUTLINE : This multi-center trial . Subjects stratify prior randomization base previous administration chemotherapy . Subjects randomize aprepitant placebo first study cycle chemotherapy cross opposite treatment second study cycle . Cisplatin-based regimen germ cell tumor contain 20mg/m2/day IV day 1 5 , first day chemotherapy administration day 1 . Permitted treatment regimen : Regimen 1 ( BEP ) Cisplatin ( 20mg/m2/day ) IV day 1 5 Etoposide ( 100 mg/m2/day ) IV day 1 5 Bleomycin 30 U/IV day 1 , 8 , 15 Regimen 2 ( EP ) Cisplatin ( 20mg/m2/day ) IV day 1 5 Etoposide ( 100 mg/m2/day ) IV day 1 5 Regimen 3 ( VIP ) Cisplatin ( 20mg/m2/day ) IV day 1 5 Ifosfamide ( 1200 mg/m2/day ) IV day 1 5 ( mesna uroprophylaxis 100 % ifosfamide dosing ) Etoposide ( 75 mg/m2/day ) IV day 1 5 Regimen 4 ( VeIP ) Cisplatin ( 20mg/m2/day ) IV day 1 5 Ifosfamide ( 1200 mg/m2/day ) IV day 1 5 ( mesna uroprophylaxis 100 % ifosfamide dosing ) Vinblastine ( 0.11 mg/kg/day ) IV day 1 2 Regimen 5 ( EC ) Cisplatin ( 20mg/m2/day ) IV day 1 5 Epirubicin ( 90 mg/m2/day ) IV day 1 Patients treat study two cycle . At completion protocol therapy patient receive additional chemotherapy discretion treat investigator . If patient require discontinuation one medication regimen , patient must discontinue study . Performance Status : - Not specify Hematopoietic : - Not specify Hepatic : - Bilirubin &lt; 3 x upper limit normal - Aspartate aminotransferase ( AST , SGOT ) &lt; 3 x upper limit normal - Alanine aminotransferase ( ALT , SGPT ) &lt; 3 x upper limit normal - Alk Phos &lt; 3 x upper limit normal Renal : - Serum Creatinine &lt; 2 mg/dL Pulmonary : - Not specify</detailed_description>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Histologic , serologic clinical evidence germ cell tumor . Patients schedule receive 5 day fractionate cisplatinbased combination chemotherapy permit regimen Prior chemotherapy allow . Patients stratify base previous treatment . Male patient 15 year age old time registration . Patient provide write informed consent authorization release personal health information . No known history anticipatory nausea vomit . No use another antiemetic agent within 72 hour prior begin chemotherapy . No known central nervous system ( CNS ) metastasis . No known hypersensitivity component study regimen . No concurrent participation clinical trial involve another investigational agent . No use warfarin study . No use agent expect induce metabolism aprepitant include : Rifampin , Rifabutin , Phenytoin , Carbamazepine , barbiturates . No use agent may impair metabolism aprepitant include : Cisapride , macrolide antibiotic ( Erythromycin , Clarithromycin , Azithromycin ) , azole antifungal agent ( Ketoconazole , Itraconazole , Voriconazole , Fluconazole ) , Amifostine , Nelfinavir Ritonavir .</criteria>
	<gender>Male</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>